Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Ibnu Sina: Jurnal Kedokteran dan Kesehatan - Fakultas Kedokteran Universitas Islam Sumatera Utara
Lubis, Ainun Basyiroh
Unknown Affiliation
Humanities Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Efficacy and Safety of Ixazomib for Newly Diagnosed Multiple Myeloma (NDMM) and Refractory or Relapsed Multiple Myeloma (RRMM): An Updated Systematic Review Lubis, Ainun Basyiroh; Santosa, Damai; Rizky, Daniel; Tandarto, Kevin; Kartiyani, Ika; Yunarvika, Vina; Ardini, Desta Nur Ewika; Setiawan, Budi; Pangarsa, Eko Adhi; Suharti, Catharina
Indonesian Journal of Cancer Vol 19, No 2 (2025): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i2.1241

Abstract

Background: Newly diagnosed multiple myeloma (NDMM) is a significant healthcare concern, comprising 1.8% of newly diagnosed cancers in the United States. Recent advancements in NDMM and refractory/relapsed multiple myeloma (RRMM) treatment, including novel agents like ixazomib, have improved patient outcomes. Ixazomib, an oral proteasome inhibitor, has shown promise in clinical trials, particularly in combination with lenalidomide and dexamethasone (IRd). This study aims to find the efficacy and safety profiles of ixazomib for NRMM and RRMM.Methods: We conducted a systematic literature review using Scopus, PubMed, Google Scholar, and ProQuest databases, focusing on randomized controlled trials (RCTs) evaluating ixazomib’s efficacy and safety in NDMM and RRMM treatment. Eligibility criteria included studies published within the last 3 years reporting data on ixazomib in NDMM and RRMM patients. Quality assessment utilized the Cochrane Risk of Bias tool for RCTs.Results: The review identified three studies from 2021–2023 demonstrating ixazomib’s efficacy and safety in MM treatment across various patient groups. Benefits included improved progression-free survival (PFS) in non-transplant NDMM, significant PFS advantage in relapsed/ refractory MM, and efficacy in transplant-ineligible NDMM induction regimens.Conclusion: Ixazomib emerges as a well-tolerated maintenance therapy offering significant PFS advantages in NDMM and RRMM, irrespective of age or frailty status. Future research, including multicenter studies, is warranted to further elucidate ixazomib’s role in MM management.
PERAN PROFILAKSIS ANTIBIOTIK DALAM PENCEGAHAN INFEKSI LUKA OPERASI: TINJAUAN SISTEMATIS: THE ROLE OF ANTIBIOTIC PROPHYLAXIS IN THE PREVENTION OF SURGICAL WOUND INFECTIONS: A SYSTEMATIC REVIEW Harahap, Surya Maratua Horas; Lubis, Ainun Basyiroh; Ayu, Mayang Sari
Ibnu Sina: Jurnal Kedokteran dan Kesehatan - Fakultas Kedokteran Universitas Islam Sumatera Utara Vol. 24 No. 2 (2025): Juli 2025
Publisher : Faculty of Medicine Universitas Islam Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30743/ibnusina.v24i2.850

Abstract

Profilaksis antibiotik praoperatif memiliki peran penting dalam mencegah infeksi situs bedah (SSI), yang dapat berkontribusi pada penurunan morbiditas, mortalitas, dan perpanjangan masa rawat inap. SSI sering terjadi pada pembedahan berisiko tinggi akibat kontaminasi bakteri. Tinjauan literatur sistematis ini bertujuan untuk mengevaluasi efektivitas profilaksis antibiotik dalam mengurangi SSI dengan memilih antibiotik yang optimal. Tinjauan ini mengikuti pedoman PRISMA 2020, dengan menggunakan basis data seperti Scopus, PubMed, Google Scholar, dan ProQuest, serta fokus pada studi yang diterbitkan dalam 10 tahun terakhir. Uji klinis acak (RCT) dan studi non-acak dimasukkan. Tiga studi memenuhi kriteria inklusi. Satu studi menunjukkan bahwa bubuk vancomycin intrawound secara signifikan mengurangi SSI pada operasi tulang belakang. Studi lain melaporkan bahwa pemberian cephalexin dan metronidazol secara oral pascaoperasi mengurangi tingkat SSI pada wanita obes setelah operasi sesar. Studi ketiga menyimpulkan bahwa profilaksis antibiotik perioperatif sama efektifnya dengan profilaksis yang diperpanjang pada operasi maksilofasial, tanpa ada manfaat tambahan dari penggunaan yang lebih lama. Temuan ini menunjukkan bahwa profilaksis antibiotik efektif dalam mencegah SSI; namun, penggunaan yang lebih lama tidak selalu memberikan manfaat tambahan dan dapat meningkatkan risiko resistensi. Penelitian lebih lanjut diperlukan untuk mengoptimalkan strategi profilaksis, dengan fokus pada uji klinis multisenter dan pengelolaan antibiotik yang bijaksana.
Co-Authors Ardini, Desta Nur Ewika Ayu, Mayang Sari Budi Setiawan Catharina Suharti Harahap, Surya Maratua Horas Kartiyani, Ika Pangarsa, Eko Adhi Rizky, Daniel Santosa, Damai Tandarto, Kevin Yunarvika, Vina